Erlotinib improves progression-free survival in early mutated non-small cell lung cancer
Munich, Germany, 21 October 2018 - Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small...







